Brigatinib

Brigatinib is a targeted therapy used for the treatment of ALK-positive non-small cell lung cancer (NSCLC). This form of lung cancer features a genetic mutation known as anaplastic lymphoma kinase (ALK) rearrangement, which causes abnormal cell growth. Brigatinib works by inhibiting the activity of ALK, thereby blocking the growth and spread of cancer cells. It is often prescribed for patients whose disease has progressed on or who are intolerant to prior ALK inhibitors such as crizotinib.